Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history.


Journal

Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 19 6 2019
medline: 18 2 2020
entrez: 19 6 2019
Statut: ppublish

Résumé

Before SNP-based risk can be incorporated in colorectal cancer (CRC) screening, the ability of these SNPs to estimate CRC risk for persons with and without a family history of CRC, and the screening implications need to be determined. We estimated the association with CRC of a 45 SNP-based risk using 1181 cases and 999 controls, and its correlation with CRC risk predicted from detailed family history. We estimated the predicted change in the distribution across predefined risk categories, and implications for recommended screening commencement age, from adding SNP-based risk to family history. The inter-quintile risk ratio for colorectal cancer risk of the SNP-based risk was 3.28 (95% CI 2.54-4.22). SNP-based and family history-based risks were not correlated (r = 0.02). For persons with no first-degree relatives with CRC, screening could commence 4 years earlier for women (5 years for men) in the highest quintile of SNP-based risk. For persons with two first-degree relatives with CRC, screening could commence 16 years earlier for men and women in the highest quintile, and 7 years earlier for the lowest quintile. This 45 SNP panel in conjunction with family history, can identify people who could benefit from earlier screening. Risk reclassification by 45 SNPs could inform targeted screening for CRC prevention, particularly in clinical genetics settings when mutations in high-risk genes cannot be identified. Yet to be determined is cost-effectiveness, resources requirements, community, patient and clinician acceptance, and feasibility with potentially ethical, legal and insurance implications.

Identifiants

pubmed: 31209717
doi: 10.1007/s10689-019-00136-6
pii: 10.1007/s10689-019-00136-6
pmc: PMC6785388
mid: NIHMS1532103
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

389-397

Subventions

Organisme : NCI NIH HHS
ID : U24 CA074794
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201300021C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA097735
Pays : United States
Organisme : NIH HHS
ID : U01 CA 122839
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074783
Pays : United States
Organisme : NIH HHS
ID : UM1 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000121C
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148107
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CN067009
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA170122
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074794
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261201300011C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201300012I
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA143237
Pays : United States
Organisme : NCI NIH HHS
ID : N01PC35142
Pays : United States
Organisme : NCI NIH HHS
ID : K05 CA152715
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA122839
Pays : United States

Références

Nat Genet. 2008 Dec;40(12):1426-35
pubmed: 19011631
Gastroenterology. 2013 Apr;144(4):799-807.e24
pubmed: 23266556
Gut. 2013 Jun;62(6):871-81
pubmed: 22490517
Nat Genet. 2007 Aug;39(8):989-94
pubmed: 17618283
Eur J Hum Genet. 2017 Jun;25(7):832-838
pubmed: 28488675
Genet Med. 2017 Mar;19(3):314-321
pubmed: 27490113
Nat Genet. 2013 Feb;45(2):191-6
pubmed: 23263487
Cancer. 2016 Sep 1;122(17):2633-45
pubmed: 27258162
Am J Hum Genet. 2013 Jun 6;92(6):1008-12
pubmed: 23731541
Nat Genet. 2007 Aug;39(8):984-8
pubmed: 17618284
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3131-9
pubmed: 20978172
Am J Epidemiol. 1992 Nov 1;136(9):1138-47
pubmed: 1462973
PLoS One. 2014 Jun 30;9(6):e101178
pubmed: 24978480
Nat Genet. 2002 May;31(1):33-6
pubmed: 11984562
Nat Commun. 2014 Aug 08;5:4613
pubmed: 25105248
Ann Oncol. 2016 Mar;27(3):429-34
pubmed: 26578737
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65
pubmed: 26677205
Nat Commun. 2015 Jul 07;6:7138
pubmed: 26151821
Nat Rev Genet. 2009 Jun;10(6):353-8
pubmed: 19434079
Nat Genet. 2007 Nov;39(11):1315-7
pubmed: 17934461
Nat Genet. 2014 Jun;46(6):533-42
pubmed: 24836286
Nat Genet. 2019 Jan;51(1):76-87
pubmed: 30510241
Nat Genet. 2008 May;40(5):623-30
pubmed: 18372905
Genet Epidemiol. 2001 Jul;21(1):1-18
pubmed: 11443730
Epidemiol Perspect Innov. 2011 Feb 27;8(1):2
pubmed: 21352566
Nat Genet. 2008 May;40(5):631-7
pubmed: 18372901
Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1619-1624
pubmed: 27539266
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):404-412
pubmed: 27799157
Nat Genet. 2012 May 27;44(7):770-6
pubmed: 22634755
J Natl Cancer Inst. 2010 Nov 3;102(21):1618-27
pubmed: 20956782
Carcinogenesis. 2014 Nov;35(11):2512-9
pubmed: 25023989
Nat Genet. 2010 Nov;42(11):973-7
pubmed: 20972440
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Am J Epidemiol. 2015 Nov 15;182(10):863-7
pubmed: 26520360
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2331-43
pubmed: 17982118
Cancer Epidemiol. 2014 Oct;38(5):583-90
pubmed: 25132422
Cancer Discov. 2013 Feb;3(2):148-57
pubmed: 23299199
PLoS Genet. 2011 Jun;7(6):e1002105
pubmed: 21655089
Future Oncol. 2016 Feb;12(4):503-13
pubmed: 26846999
Sci Rep. 2015 May 20;5:10442
pubmed: 25990418

Auteurs

Mark A Jenkins (MA)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia. m.jenkins@unimelb.edu.au.
Centre for Cancer Research, The University of Melbourne, Parkville, VIC, Australia. m.jenkins@unimelb.edu.au.

Aung K Win (AK)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.
Centre for Cancer Research, The University of Melbourne, Parkville, VIC, Australia.
Genetic Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia.

James G Dowty (JG)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.

Robert J MacInnis (RJ)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.

Enes Makalic (E)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.

Daniel F Schmidt (DF)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.

Gillian S Dite (GS)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.

Mirosl Kapuscinski (M)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.

Mark Clendenning (M)

Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.

Christophe Rosty (C)

Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.
Envoi Specialist Pathologists, Herston, QLD, Australia.
School of Medicine, University of Queensland, Herston, QLD, Australia.

Ingrid M Winship (IM)

Genetic Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia.
Department of Medicine, The University of Melbourne, Parkville, VIC, Australia.

Jon D Emery (JD)

Department of General Practice, Centre for Cancer Research, University of Melbourne, Parkville, VIC, Australia.
The Primary Care Unit, Department of Public Health & Primary Care, University of Cambridge, Cambridge, UK.

Sibel Saya (S)

Department of General Practice, Centre for Cancer Research, University of Melbourne, Parkville, VIC, Australia.
The Primary Care Unit, Department of Public Health & Primary Care, University of Cambridge, Cambridge, UK.

Finlay A Macrae (FA)

Genetic Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia.
Department of Medicine, The University of Melbourne, Parkville, VIC, Australia.
Colorectal Medicine and Genetics, Royal Melbourne Hospital, Parkville, VIC, Australia.

Dennis J Ahnen (DJ)

University of Colorado School of Medicine, Denver, CO, USA.

David Duggan (D)

Office of the Chief Operating Officer, Translational Genomics Research Institute, Phoenix, AZ, USA.

Jane C Figueiredo (JC)

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Noralane M Lindor (NM)

Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, AZ, USA.

Robert W Haile (RW)

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

John D Potter (JD)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
School of Public Health, University of Washington, Seattle, WA, USA.
Centre for Public Health Research, Massey University, Wellington, New Zealand.

Michelle Cotterchio (M)

Cancer Care Ontario, Toronto, ON, Canada.

Steven Gallinger (S)

Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.

Polly A Newcomb (PA)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
School of Public Health, University of Washington, Seattle, WA, USA.

Daniel D Buchanan (DD)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.
Centre for Cancer Research, The University of Melbourne, Parkville, VIC, Australia.
Genetic Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia.
Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.

Graham Casey (G)

Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.

John L Hopper (JL)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.
Centre for Cancer Research, The University of Melbourne, Parkville, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH